Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04962906
Other study ID # 5143
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date July 5, 2021
Est. completion date August 15, 2021

Study information

Verified date July 2021
Source Ministerio de Salud de Ciudad Autónoma de Buenos Aires
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To determine whether a heterologous vaccination regimen in individuals with no known previous history of COVID-19 is non-inferior to that observed with counterpart regimens currently in use in Argentina.


Description:

The Covid-19 disease caused by the SARS-COV 2 virus has caused a pandemic with more than 180 million cases worldwide and more than 4 million deaths. In Argentina, this pandemic has had a significant impact, with about 4.5 million cases and about 95,000 deaths. In no more than nine months, medical science developed different vaccines to prevent new cases and mitigate this pandemic. At the time of the presentation of this research protocol, there are four vaccines for the prevention of COVID-19 approved for emergency use by the National Administration of Medicines, Food and Medical Technology (ANMAT). Of these, three (1-3) are currently available and are part of the vaccination campaign. Of these three vaccines, two use a non-replicating viral vector platform (Gam-COVID-Vac and ChAdOx1 nCoV-19) while one uses an inactivated virus platform (BBIBP-CorV). All require the administration of two doses with an administration interval of at least 21 days. All these vaccines were designed to be used with a homologous two-dose regimen. However, for both logistical and biomedical reasons, the need to use vaccines in heterologous regimens (one dose of one vaccine and a second dose of another vaccine) is emerging worldwide. The efficacy and safety of this type of regimen has not yet been demonstrated. In Argentina, there are a large number of people who currently have one dose of Gam-COVID-Vac vaccine and who - even after a period of ≥21 days - have not received the second component. At the same time, the provision of the second component of the Gam-COVID-Vac vaccine is delayed due to production and distribution logistics. As of June 2021, among the universe of people vaccinated with Gam-COVID, residents of CABA, vaccinated in establishments in the City of Buenos Aires - and excluding deceased and infected people - there were a total of 325,788 people with one dose and ≥22 and ≤90 days since the first dose was administered. In a context of high viral circulation, it is desirable to try to vaccinate as much of the population as possible with a full schedule in the shortest possible time. In addition, new variants of SARS-COV2 virus possessing the E384K genomic variant such as the gamma strain (formerly Manaus), the beta strain (known as South African) and the Delta strain (also known as Indian) have the ability to evade the immune system and therefore most laboratories that have developed vaccines recognise that the efficacy of the vaccines requires two doses. The use of heterologous schedules is a source of active research in various parts of the world (4-6). However, most of this research is testing the combination of a combination schedule that includes an mRNA vaccine. There is an ongoing study sponsored by the Gamaleya Institute and AstraZeneca that is evaluating the immunogenicity of a scheme similar to the one proposed in this trial. Results from this joint trial would not be available until mid-October (7). No trials have evaluated the combination of rAd26-rAd5 and BBIBP-CorV. This study will attempt to determine whether administration of a heterologous regimen combining a first dose of Gam-COVID-Vac with a second dose of ChAdOx1 nCoV-19 or BBIBP-CorV results in non-inferior immunogenicity to the homologous regimen used. The present protocol is therefore oriented to respond to a practical management need and to guarantee the best possible protection to the population through two doses, which is what is considered worldwide as "complete vaccination" according to WHO for the vaccines used by Argentina. The proposed protocol is a pragmatic and public health oriented clinical trial, whose primary objective is to establish whether there are indicators that allow the implementation of a heterologous vaccination scheme. For this, a surrogate endpoint will be used, which is immunogenicity measured by the presence of antibodies against protein S. In addition, the safety of the combination will be evaluated in terms of monitoring self-reported and non-self-reported clinical events by patients.


Recruitment information / eligibility

Status Completed
Enrollment 192
Est. completion date August 15, 2021
Est. primary completion date August 5, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 21 Years to 65 Years
Eligibility Inclusion Criteria: - Persons who have received a dose of Gam-COVID-Vac more than 30 days and less than 90 days ago. - Age between 21 and 65 years. - Both genders. - Who have voluntarily agreed to participate in the clinical trial and have provided informed consent. Exclusion Criteria: - Known history of COVID in the 6 months prior to study inclusion. - Known or suspected immunocompromised status by the study investigator for any cause. - Use of oral or parenteral corticosteroids in the last 30 days. - Known history of allergy to any vaccine. - History of anaphylaxis. - Pregnant or lactating women. - Known history of autoimmune diseases. - Persons under treatment for any neoplastic disease within the last 6 months. - Any serious illness or condition at the discretion of the study investigator (including but not limited to the presence of chronic obstructive pulmonary disease, heart failure, poorly controlled hypertension, poorly controlled diabetes, renal failure). - Planned medical procedures within two months of randomisation. - Previous vaccination within the last 30 days with any vaccine. - Known participation in an ongoing clinical trial. - Ongoing acute illness. - Fever (=37.8 C) at the time of randomisation.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Gam-COVID-Vac / Gam-COVID-Vac
A comparison of antibody levels against protein S will be performed using the Gam-COVID-Vac / Gam-COVID-Vac group as a control group and the Gam-COVID-Vac / ChAdOx1 nCoV-19 and Gam-COVID-Vac / BBIBP-CorV groups as comparators.

Locations

Country Name City State
Argentina Ministerio de Salud de la Ciudad Autónoma de Buenos Aires Ciudad Autónoma de Buenos Aires

Sponsors (1)

Lead Sponsor Collaborator
Ministerio de Salud de Ciudad Autónoma de Buenos Aires

Country where clinical trial is conducted

Argentina, 

Outcome

Type Measure Description Time frame Safety issue
Primary ELISA assessment of IgG anti Spike (UI/ml) To determine whether a heterologous vaccination regimen in individuals with no known previous history of COVID-19 is non-inferior to that observed with currently used counterpart regimens.
The determination of the antibody concentration in each of the study arms will be assessed by measuring the IgG antibody concentration using ELISA expressed in IU/ml.
28 days
Primary Serious adverse events Adverse events of special interest To report the combine and specific rate of serious adverse defined as death for any reason, any life-threatening event or any event that require inpatient hospitalization. 28 days
Secondary Neutralising antibodies against SARS-CoV-2 28 days
See also
  Status Clinical Trial Phase
Recruiting NCT05918939 - UNAIR Inactivated COVID-19 Vaccine as Heterologue Booster (Immunobridging Study) Early Phase 1
Active, not recruiting NCT06272253 - UNAIR Inactivated COVID-19 Vaccine INAVAC as Heterologue Booster (Immunobridging Study) in Adolescent Subjects Early Phase 1
Recruiting NCT05298800 - Combined Immunization of COVID-19 Inactivated Vaccine With QIV and PPV23 Phase 4
Recruiting NCT05185817 - Effectiveness of COVID-19 Vaccine in Hematopoietic Stem Cell Transplant Patients Phase 2
Not yet recruiting NCT04876885 - The Future of Viral Communications: Video-Based Health Promotion Strategies for COVID-19 Vaccinations N/A
Completed NCT05373459 - Effect of a Third COVID-19 Booster Among Health Care Workers
Active, not recruiting NCT05571657 - COVID-19 Booster Dose Reminder/Recall for Adolescents N/A
Completed NCT04888793 - Immune Response to Anti COVID-19 Vaccine in Immunocompromised Patients: a Cohort Study
Completed NCT04881396 - Response of Haemodialysis Patients to BNT162b2 mRNA Cov-19 Vaccine
Recruiting NCT04871165 - Analysis of Immunogenicity, Safety and Efficacy of COVID-19 Vaccines in Immunosuppressed Individuals
Active, not recruiting NCT05293665 - Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine Phase 3
Active, not recruiting NCT05405283 - Randomized, Single-blinded, Multicenter Trial Comparing the Immune Response to a 2nd Booster Dose of COVID-19 mRNA Vaccine (Pfizer-BioNTech) or Sanofi /GSK B.1.351 Adjuvanted Vaccine in Adults Phase 3
Recruiting NCT05508477 - UNAIR Inactivated COVID-19 Vaccine Phase III (Immunobridging Study) Phase 3
Recruiting NCT05471635 - Variables Influencing Anti-COVID-19 Vaccinations Around the World: an Analysis Conducted on Aggregated Data Sourced From Institutional Databases to Understand Whether and How Different Variables Could Affect the Vaccine Coverage (WORLDCOV: Worldwide Determinants of COVID-19 Vaccination)
Recruiting NCT06282692 - INAVAC Vaccine Phase III (Immunobridging Study) in Healthy Population Aged 12 to 17 Years Old Phase 3
Completed NCT05406908 - Intradermal Tozinameran for Patients With Immune-mediated Dermatologic Diseases Phase 4
Recruiting NCT04895007 - Comparative Evaluation of Covid-19 Vaccines Response
Recruiting NCT05831826 - Effectiveness and Safety of the Inactivated COVID-19 Vaccine in Thousands of Patients With Autoimmune Diseases in China
Recruiting NCT05096260 - Getting to Yes, Michigan! (G2YMI) N/A
Active, not recruiting NCT05027672 - Strategies for Combining the First Component of Sputnik V With Other Adenoviral or mRNA-based Vaccines. Phase 2